PRMT5

Assets acting on this target.

Notes
original target text: PRMT5 inhibitor

Protein arginine methyltransferase 5 (PRMT5) is an enzyme that adds methyl groups to arginine residues on histone proteins and many other cellular proteins, thereby influencing gene transcription, RNA splicing, and DNA damage repair. Because PRMT5 activity supports the proliferation of many cell types, particularly rapidly dividing cancer cells, its enzymatic function has become a target for pharmacological inhibition. A key biological rationale for this approach centers on tumors that carry deletion of the neighboring gene MTAP, which is frequently co-deleted with a tumor suppressor locus in several solid tumors. Loss of MTAP causes accumulation of a metabolite that partially inhibits PRMT5, creating a dependency state in which further pharmacological suppression of PRMT5 selectively harms MTAP-deleted cancer cells while sparing normal tissue that retains MTAP. This concept, known as synthetic lethality, underlies interest in PRMT5 inhibitors as a way to achieve a therapeutic window in an epigenetic target that would otherwise be broadly essential and difficult to inhibit safely. Small-molecule inhibitors of PRMT5 are being explored primarily in oncology, with particular relevance to cancers defined by this specific genetic deletion, illustrating a broader strategy of exploiting tumor-specific metabolic vulnerabilities rather than targeting a pathway unique to cancer cells alone.

By indication

Related mechanisms

PRMT5 drugs compared

6 drugs, stage by indication
6 drugs acting on PRMT5: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
AZD3470AstraZenecasmall moleculePhase 1/2Not recorded
BAY 3713372Bayer, Suzhou Puhe BioPharma Co., Ltd.small moleculePhase 1/2Not recorded
TNG456Tango Therapeuticssmall moleculePhase 1/2Phase 1/2 in Glioblastoma; Phase 1/2 in Non-Small Cell Lung Cancer
VopimetostatTango Therapeuticssmall moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer; Phase 1/2 in Pancreatic Ductal Adenocarcinoma
HSK41959Haisco Pharmaceutical Groupsmall moleculePhase 1Not recorded
IDE892IDEAYA Biosciencessmall moleculePhase 1Phase 1 in Non-Small Cell Lung Cancer

← all mechanisms